However, the association between NRF2 expression and radioresistance of cancer cells in various tumor types, as in lung cancer (156, 157), prostate cancer (158), and nasopharyngeal cancer (159), renders it a good therapeutic target to increase the sensitivity to the treatment. This evidence concerns the gene NFE2L2 and nasopharyngeal carcinoma.